Previously, we showed that peptide mimetics-mediated selective targeting of the STRN3-containing PP2A can restore the Hippo signaling against cancer and that targeting STRIPAK complex can inhibit DNA repair therefore sensitizing cancer to PARP inhibition (16, 26). Here, PTPA is linked to cancer.